• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Nogapendekin alfa Inbakicept-pmln (Anktiva) with BCG: A Promising Arsenal in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Intervention.诺加彭德金α英巴奇普-pmln（安克蒂瓦）联合卡介苗：卡介苗无反应性非肌肉浸润性膀胱癌干预的有前景的武器。
Adv Pharm Bull. 2025 Mar 29;15(1):4-6. doi: 10.34172/apb.43870. eCollection 2025 Apr.
2
Nogapendekin alfa Inbakicept: First Approval.尼戈宾卡丁-α（Inbakicept）：首个获批。
Drugs. 2024 Jul;84(7):867-874. doi: 10.1007/s40265-024-02060-1. Epub 2024 Jul 5.
3
Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial.诺加彭德金α-免疫内肽酶-聚麦芽糖纳米粒：卡介苗无反应性非侵袭性膀胱癌的首个批准里程碑：社论
Ann Med Surg (Lond). 2024 Sep 20;86(11):6386-6388. doi: 10.1097/MS9.0000000000002591. eCollection 2024 Nov.
4
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.卡介苗无反应性非肌层浸润性膀胱癌的保膀胱治疗：国际膀胱癌小组关于最佳治疗顺序和患者选择的建议
Eur Urol. 2024 Dec;86(6):516-527. doi: 10.1016/j.eururo.2024.08.001. Epub 2024 Aug 24.
5
Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer.高级别非肌层浸润性膀胱癌和局限性肌层浸润性膀胱癌的膀胱保留现状
Curr Oncol Rep. 2025 Apr 30. doi: 10.1007/s11912-025-01657-3.
6
In brief: Anktiva for bladder cancer.简而言之：用于膀胱癌的Anktiva。
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-e106. doi: 10.58347/tml.2024.1705e.
7
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.白细胞介素-15 超级激动剂 NAI 在卡介苗无应答性非肌肉浸润性膀胱癌中的作用。
NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.
8
Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer.针对高危非肌层浸润性膀胱癌的新兴保膀胱治疗方法。
Bladder Cancer. 2025 Jun 26;11(2):23523735251348842. doi: 10.1177/23523735251348842. eCollection 2025 Apr-Jun.
9
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.卡介苗治疗失败的非肌层浸润性膀胱癌的未满足需求：国际膀胱癌小组的系统评价和成本效益分析
Eur Urol Oncol. 2025 Feb;8(1):216-229. doi: 10.1016/j.euo.2024.10.012. Epub 2024 Nov 15.
10
Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer.N-803 联合卡介苗治疗卡介苗无应答性非肌肉浸润性膀胱癌的 2/3 期试验中的生活质量。
Urol Pract. 2024 Mar;11(2):367-375. doi: 10.1097/UPJ.0000000000000517. Epub 2024 Jan 16.

本文引用的文献

1
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.卡介苗治疗失败的非肌层浸润性膀胱癌的未满足需求：国际膀胱癌小组的系统评价和成本效益分析
Eur Urol Oncol. 2025 Feb;8(1):216-229. doi: 10.1016/j.euo.2024.10.012. Epub 2024 Nov 15.
2
Comparison between N-803 and Erdafitinib in Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.N-803与厄达替尼在卡介苗无反应性非肌肉浸润性膀胱癌中的比较
Cancers (Basel). 2024 Oct 11;16(20):3445. doi: 10.3390/cancers16203445.
3
Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC.BCG 无应答性非肌层浸润性膀胱癌不同治疗方式的成本效果分析。
BJU Int. 2024 Oct;134(4):582-588. doi: 10.1111/bju.16332. Epub 2024 Mar 16.
4
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer.BCG 与非肌肉浸润性膀胱癌的 BCG 治疗替代疗法。
Curr Oncol. 2024 Feb 16;31(2):1063-1078. doi: 10.3390/curroncol31020079.
5
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.白细胞介素-15 超级激动剂 NAI 在卡介苗无应答性非肌肉浸润性膀胱癌中的作用。
NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.
6
Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.用于 BCG 无应答的高危非肌肉浸润性膀胱癌的新型免疫治疗选择。
Cancer Med. 2023 Dec;12(24):21944-21968. doi: 10.1002/cam4.6768. Epub 2023 Dec 1.
7
Re: IL-15 Superagonist NAI in BCG-Unresponsive Non-muscle-invasive Bladder Cancer.关于：卡介苗无反应性非肌层浸润性膀胱癌中的白细胞介素-15超激动剂NAI
Eur Urol. 2023 Jun;83(6):581. doi: 10.1016/j.eururo.2023.01.009. Epub 2023 Feb 1.
8
Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer.IL-15 类似物（N-803）联合卡介苗（BCG）治疗膀胱癌的安全性、耐受性和长期临床结局。
Oncoimmunology. 2021 May 3;10(1):1912885. doi: 10.1080/2162402X.2021.1912885.
9
Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.膀胱内注射ALT-803和卡介苗治疗可减轻致癌物诱导的膀胱癌大鼠模型中的肿瘤负担；细胞因子产生和自然杀伤细胞扩增的作用。
PLoS One. 2014 Jun 4;9(6):e96705. doi: 10.1371/journal.pone.0096705. eCollection 2014.
10
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.膀胱原位癌且卡介苗治疗禁忌或失败的患者的膀胱内 VALrubicin。
Urol Oncol. 2013 Nov;31(8):1635-42. doi: 10.1016/j.urolonc.2012.04.010. Epub 2012 May 9.

Nogapendekin alfa Inbakicept-pmln (Anktiva) with BCG: A Promising Arsenal in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Intervention.

作者信息

MohanaSundaram ArunSundar, Raja Velmurugan, Kamalakannan Yeshwanth, Islam Md Aminul

机构信息

School of Pharmacy, Sathyabama Institute of Science and Technology, Jeppiaar Nagar, Rajiv Gandhi Salai, Chennai 600119. Tamilnadu, India.

COVID-19 Diagnostic Lab, Department of Microbiology, Noakhali Science and Technology University, Noakhali-3814, Bangladesh.

出版信息

Adv Pharm Bull. 2025 Mar 29;15(1):4-6. doi: 10.34172/apb.43870. eCollection 2025 Apr.

DOI:10.34172/apb.43870
PMID:40636313
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12235375/
Abstract
摘要